Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Healthcare: Is Valeant Pharmaceuticals the Turnaround Story of the Century?


Healthcare: Is Valeant Pharmaceuticals the Turnaround Story of the Century?

This week, Valeant Pharmaceuticals (NYSE: VRX) reported its earnings, and the market rewarded it with a 17% stock price bump. While the company's shares are still down 95% from their 2016 highs, some investors are wondering if Valeant is actually starting to turn things around -- and if now might be a good time to buy in.

In this week's episode of Industry Focus: Healthcare, analysts Kristine Harjes and Todd Campbell go over the report to explain where the company is doing well, where it's still struggling, and what the long-term future could hold for it. They also discuss another company that just reported earnings -- Keryx Biopharmaceuticals (NASDAQ: KERX), shares of which fell 17% even though it just won FDA approval to sell a drug into a huge new indication. Find out why the market shrank away from the company, and why today's huge drop may have been an overreaction.

A full transcript follows the video.

Continue reading


Source: Fool.com

Like: 0
Share

Comments